Stonebridge

Stonebridge Biopharma was a specialty pharmaceutical company focused on the acquisition, development, and commercialization of innovative pharmaceutical products. The company's primary business model involved identifying late-stage or commercial assets that could be optimized through targeted marketing and clinical lifecycle management. Its most notable achievement was securing the U.S. rights to Pennsaid 2%, a topical nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis pain. Shortly after acquiring these rights, the company was acquired by Horizon Pharma, which integrated the product into its primary care business unit.